Spanish pharmaceutical firm Almirall forecast on Monday a drop in core earnings this year after a 15.8% decline in 2022 due to increased investment in research and development, as well as lower sales in the United States.
Reuters HealthNovartis on Monday announced the appointment of Gilbert Ghostine as chairman-designate of Sandoz, the generics unit Novartis wants to spin off later this year.
Clinical trials for BioNTech’s cancer vaccines should start this year in Britain, marking an important step towards their possible sale on the open market, the German company’s top executive Ugur Sahin told magazine Der Spiegel.
ReutersTravere Therapeutics said on Friday the U.S. health regulator has granted accelerated approval to its drug to treat a type of chronic kidney disease, IgAN, in adults with a high risk of advancing to kidney failure.
The U.S. Food and Drug Administration has approved Apellis Pharmaceuticals Inc.’s drug to treat an advanced eye disorder that is one of the leading causes of blindness globally, the company said on Friday.
Becton Dickinson’s C.R. Bard Inc. on Friday won a ruling from a U.S. appeals court reinstating three patents related to its PowerPort devices for delivering repeated medical injections.
The U.S. government will select the 10 costliest prescription medicines to Medicare for negotiating prices with drugmakers starting early next year, the program’s top official said on Friday.
Genome engineering company Replay and The University of Texas’ MD Anderson Cancer Center have joined forces to launch Syena, an oncology product company.
J&J’s Janssen Pharmaceutical has given up on an RNAi therapeutic being developed for one of biotech’s hottest targets: non-alcoholic steatohepatitis (NASH).
Bausch + Lomb Corp. on Wednesday named Brent Saunders, the former chief executive officer of Allergan, as its CEO and chairman of board, marking his return to the Canadian eye-care company after nearly a decade.
